{
  "trial_id": "NCT00678652",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Age 18-45 years",
      "label": "met"
    },
    {
      "criterion": "Able to give informed consent, understands risks and benefits of study, assents to use of blood samples for future research; understands and is willing to comply with all protocol procedures and time commitments",
      "label": "met"
    },
    {
      "criterion": "Females must have a negative urine pregnancy test on vaccination day before each dose AND agree to practice an effective birth control method as necessary, for 6 months after the first vaccination",
      "label": "met"
    },
    {
      "criterion": "High levels of baseline bactericidal antibodies against the vaccine strain on screening (>1:16) and/or throat carriage of Neisseria meningitidis at time of screening",
      "label": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "Current or history of significant organ/system disease",
      "label": "not_met"
    },
    {
      "criterion": "History of allergy to any vaccine",
      "label": "not_met"
    },
    {
      "criterion": "Positive test for HBsAg or hepatitis C antibody",
      "label": "not_met"
    }
  ],
  "notes": "The patient has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%. He was diagnosed with atypical hemolytic uremic syndrome.",
  "_meta": {
    "topic_id": "68",
    "trial_id": "NCT00678652",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}